芬兰鼻咽癌的预后：一项全国性研究。

Outcome of nasopharyngeal carcinoma in Finland: A nationwide study.

机构信息

a Department of Otorhinolaryngology-Head and Neck Surgery , Turku University Hospital and University of Turku , Turku , Finland.

b Department of Pathology , University of Turku and Turku University Hospital , Turku , Finland.

出版信息

Acta Oncol. 2018 Feb;57(2):251-256. doi: 10.1080/0284186X.2017.1346378. Epub 2017 Jul 7.

DOI:10.1080/0284186X.2017.1346378

PMID:28686479

Abstract

BACKGROUND

Nasopharyngeal carcinoma (NPC) is uncommon in western countries and data on the outcome and histological presentation are scarce in nonendemic areas. We report here the outcome on all patients with NPC treated in Finland between 1990 and 2009.

MATERIAL AND METHODS

The Finnish Cancer Registry database was used to identify the patients. Histopathological specimens and clinical records were reviewed to confirm the histological subtypes, prognostic factors, treatment techniques and outcome across different stage groups.

RESULTS

Primary NPC was identified in 207 patients and 42 (20%) had keratinizing squamous cell carcinoma (SCC). The stage distribution was: I, 11%; II, 25%; III, 39%; IV, 25%. Of 191 patients treated with curative intent 85 (44%) received radiotherapy and 106 (56%) chemoradiotherapy. The five-year overall survival for all patients was 57% and for stages I-IV 87%, 69%, 55% and 31%, respectively. The five-year disease-specific and overall survival of all patients treated between 1990 and 1999 were 58% and 49%, and those between 2000 and 2009 66% and 63%, respectively.

CONCLUSIONS

While survival rates are improving and comparable to other western countries they remain inferior to those of endemic countries. This may reflect the different biology of NPC in nonendemic areas, where keratinizing SCC is common.

摘要

背景

鼻咽癌（NPC）在西方国家并不常见，在非流行地区，关于其结局和组织学表现的数据也很匮乏。我们在此报告了 1990 年至 2009 年间在芬兰接受治疗的所有 NPC 患者的结局。

材料与方法

我们使用芬兰癌症登记数据库来确定患者。对组织病理学标本和临床记录进行了回顾，以确认不同分期组别的组织学亚型、预后因素、治疗技术和结局。

结果

共发现 207 例原发性 NPC，其中 42 例（20%）为角化鳞状细胞癌（SCC）。分期分布为：I 期，11%；II 期，25%；III 期，39%；IV 期，25%。191 例接受根治性治疗的患者中，85 例（44%）接受了放疗，106 例（56%）接受了放化疗。所有患者的 5 年总生存率为 57%，I-IV 期分别为 87%、69%、55%和 31%。1990 年至 1999 年期间治疗的所有患者的 5 年疾病特异性生存率和总生存率分别为 58%和 49%，2000 年至 2009 年期间分别为 66%和 63%。